IOVANCE BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $26.00K.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $15.00K, a 99.54% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $3.27M, a 5084.13% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $63.00K, a 96.16% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.64M, a 95.10% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $26.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.00K 10-Q · filed 2026-05-07 | $2.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.27M 10-K · filed 2026-02-24 |
| 2024-09-30 | $713.00K 10-Q · filed 2025-11-06 | $1.48M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $390.00K 10-Q · filed 2025-08-07 | $762.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $364.00K 10-Q · filed 2025-05-08 | $427.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $63.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $55.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.64M 10-K · filed 2025-02-27 |
| 2022-09-30 | $225.00K 10-Q · filed 2023-11-07 | $5.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $25.72M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.42M 10-Q · filed 2023-05-10 | $28.46M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $33.53M 10-K · filed 2024-02-28 |
| 2021-09-30 | $20.77M 10-Q · filed 2022-11-03 | $32.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.74M 10-Q · filed 2022-08-04 | $13.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $6.48M 10-Q · filed 2022-05-05 | $12.19M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.66M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.52M 10-Q · filed 2021-11-04 | $8.91M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $1.24M 10-Q · filed 2021-08-05 | $8.16M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $3.95M 10-Q · filed 2021-05-06 | $10.32M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $6.44M 10-K · filed 2022-02-24 |
| 2019-09-30 | $762.00K 10-Q · filed 2020-11-05 | $5.83M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $3.40M 10-Q · filed 2020-08-06 | $6.60M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $69.00K 10-Q · filed 2020-05-05 | $4.40M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $9.96M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.54M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $1.20M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $5.63M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $5.62M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $626.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $241.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | |
| 2015-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $255.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |